Company / SG&A Expense
BioAtla, Inc. SG&A Expense History
FY2021-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$28.8M
FY2022
5-year range
$28.8M / $38.4M
FY2021-FY2022
Trend
-25.0%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
$29M in FY2022.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2022, sg&a expense decreased 25.0% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.29 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $28.8M | -25.0% |
| FY2021 | $38.4M | - |
As of FY2022 · SEC Form 10-K · Last checked Jun 21, 2026